|
|||||
|
|
Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass |
|
| Authors: | D L Kendler L Bessette C D Hill D T Gold R Horne S F Varon J Borenstein H Wang H-S Man R B Wagman S Siddhanti D Macarios H G Bone |
| Institution: | 1. Prohealth Clinical Research, University of British Columbia, 600–1285 West Broadway, Vancouver, BC, V6H 3X8, Canada 2. Le Centre Hospitalier Universitaire de Québec, Pavillon CHUL, 2705 Boul. Laurier, Quebec City, QC, Canada, G1V 4G2 3. RTI Health Solutions, RTI International, 200 Park Offices Drive, P.O. Box?12194, Research Triangle Park, NC, 27709, USA 4. Center for Aging, Duke University Medical Center, P.O. Box?3003, Duke Medical Center, Durham, NC, 27710, USA 5. Centre for Behavioral Medicine, The School of Pharmacy, University of London, 29–39 Brunswick Square, London, WC1N 1AX, UK 6. Allergan, 2525 Dupont Drive, Irvine, CA, 92612, USA 7. Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320, USA 8. Amgen Inc., 240 Cambridge Science Park, Milton Road, Cambridge, CB4 0WD, UK 10. Stanford University School of Medicine, Stanford, CA, USA 9. Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA, 94080, USA 11. Michigan Bone and Mineral Clinic, P.C., 22201 Moross Road, Suite 260, Detroit, MI, 48236, USA |
| Abstract: | SummaryThe Preference and Satisfaction Questionnaire (PSQ) compares patient preference and satisfaction between a 6-month subcutaneous injection and weekly oral tablet for treatment of bone loss. Patients preferred and were more satisfied with a treatment that was administered less frequently, suggesting the acceptability of the 6-month injection for treatment of bone loss.IntroductionThe PSQ compares patient preference and satisfaction between a 6-month subcutaneous injection and a weekly oral tablet for treatment of bone loss.MethodsPostmenopausal women with low bone mass who enrolled in two separate randomized phase 3 double-blind, double-dummy studies received a 6-month subcutaneous denosumab injection (60 mg) plus a weekly oral placebo or a weekly alendronate tablet (70 mg) plus a 6-month subcutaneous placebo injection. After 12 months, patients completed the PSQ to rate their preference, satisfaction, and degree of bother with each regimen.ResultsMost enrolled patients (1,583 out of 1,693; 93.5%) answered ≥1 item of the PSQ. Significantly more patients preferred and were more satisfied with the 6-month injection versus the weekly tablet (P?<?0.001). More patients reported no bother with the 6-month injection (90%) than the weekly tablet (62%).ConclusionPatients preferred, were more satisfied, and less bothered with a 6-month injection regimen for osteoporosis. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |